Wockhardt · NSE: WOCKPHARMA · BSE: 532300
Q4 FY24 results · Jan–Mar 2024
Wockhardt reported revenue from operations of ₹700.00 crore (up 3.2% from Q4 FY23) and net loss of ₹177.00 crore for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 700.00 | 678.00 | +3.2% | 701.00 | −0.1% |
| Other income | 54.00 | 32.00 | +68.8% | 8.00 | +575.0% |
| Total income | 754.00 | 710.00 | +6.2% | 709.00 | +6.3% |
| Profit before tax | (180.00) | (193.00) | Loss narrowed | (87.00) | Loss widened |
| Net profit for the period | (177.00) | (237.00) | Loss narrowed | (86.00) | Loss widened |
| Attributable to shareholders of the company | (169.00) | (208.00) | Loss narrowed | (83.00) | Loss widened |
| EPS, basic (₹) | (11.64) | (14.37) | Loss narrowed | (5.75) | Loss widened |
| Net margin (%) | -25.3 | -35.0 | -12.3 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 355.00 | 291.00 | +22.0% | 288.00 | +23.3% |
| Other income | 24.00 | 29.00 | −17.2% | 5.00 | +380.0% |
| Total income | 379.00 | 320.00 | +18.4% | 293.00 | +29.4% |
| Profit before tax | (126.00) | (289.00) | Loss narrowed | (74.00) | Loss widened |
| Net profit for the period | (126.00) | (299.00) | Loss narrowed | (74.00) | Loss widened |
| EPS, basic (₹) | (8.71) | (20.80) | Loss narrowed | (5.14) | Loss widened |
| Net margin (%) | -35.5 | -102.7 | -25.7 |
Consolidated
- Filed with BSE
- 07 Jun 2024, 18:49 IST
- Board meeting
- 28 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Jun 2024, 18:49 IST
- Board meeting
- 28 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE